Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Common Variations of DNA Repair Genes are Associated with Response to Platinum-based Chemotherapy in NSCLCs

  • Li, Xian-Dong (Department of Respiratory Medicine, Huaihe Hospital, Henan University) ;
  • Han, Ji-Chang (Department of Respiratory Medicine, Huaihe Hospital, Henan University) ;
  • Zhang, Yi-Jie (Department of Respiratory Medicine, Huaihe Hospital, Henan University) ;
  • Li, Hong-Bing (Department of Respiratory Medicine, Huaihe Hospital, Henan University) ;
  • Wu, Xue-Yan (Department of Respiratory Medicine, Huaihe Hospital, Henan University)
  • Published : 2013.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Aim: Individual differences in chemosensitivity and clinical outcome of non-small-cell lung cancer (NSCLC) patients may be induced by host inherited factors. We investigated the impact of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln gene polymorphisms on the efficacy of platinum-based chemotherapy in NSCLC patients. Methods: A total of 496 were consecutively selected from the Affiliated Hospital of Nantong University between Jan. 2003 and Nov. 2006, and all patients were followed-up until Nov. 2011. The genotyping of XPD Arg156Arg, XPD Asp312Asn, XPD Asp711Asp and XPD Lys751Gln was conducted by duplex polymerase-chain-reaction with the confronting-two-pair primer methods. Results: Individuals with XPD 312 C/T+T/T and XPD 711 C/T+T/T exhibited poor responses to chemotherapy when compared with the wild-type genotype, with adjusted ORs(95% CI) of 0.67(0.38-0.97) and 0.54(0.35-0.96), respectively. Cox regression showed the median PFS and OS of patients of XPD 312 C/T+T/T genotype and XPD 711 C/T+T/T genotype to be significantly lower than those with wild-type homozygous genotype. Conclusion: We found polymorphisms in XPD to be associated with response to platinum-based chemotherapy in NSCLC, and our findings provide information for therapeutic decisions for individualized therapy.

Keywords

References

  1. Ada AO, C Kunak S, Hancer F, et al (2010). CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. Neoplasma, 57, 512-21. https://doi.org/10.4149/neo_2010_06_512
  2. Azuma K, Komohara Y, Sasada T, et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci, 98, 1336-43. https://doi.org/10.1111/j.1349-7006.2007.00557.x
  3. Butkiewicz D, Drosik A, Suwiński R, et al (2012). Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer, 131, E1100-8. https://doi.org/10.1002/ijc.27596
  4. Duan XL, Gong H, Zeng XT, et al (2012). Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 13, 3299-303. https://doi.org/10.7314/APJCP.2012.13.7.3299
  5. Gurubhagavatula S, Liu G, Park S, et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-smallcell lung cancer patients treated with platinum chemotherapy. J Clin Oncol, 22, 2594-601. https://doi.org/10.1200/JCO.2004.08.067
  6. International Agency for Research on Cancer (2008). Lung cancer incidence, Mortality and Prevalence Worldwide in 2008. http://globocan.iarc.fr/factsheet.asp.
  7. Lord RVN, Brabender J, Gandara D, et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
  8. Lunn RM, Helzlsouer KJ, Parshad R, et al (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis, 21, 551-5. https://doi.org/10.1093/carcin/21.4.551
  9. Mi Y, Zhang L, Feng N, et al (2012). Impact of Two Common Xeroderma Pigmentosum Group D (XPD) Gene Polymorphisms on Risk of Prostate Cancer. PLoS One, 7, e44756. https://doi.org/10.1371/journal.pone.0044756
  10. Monaco R, Rosal R, Dolan MA, et al (2009). Conformational effects of a common codon 751 polymorphism on the Cterminal domain of the xeroderma pigmentosum D protein. J Carcinog, 8, 12. https://doi.org/10.4103/1477-3163.54918
  11. J Carcinog, Provencio M, Camps C, Cobo M, et al (2012). Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol, 70, 883-90. https://doi.org/10.1007/s00280-012-1985-9
  12. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  13. Spitz MR, Wu XF, Wang YF, et al (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res, 61, 1354-7.
  14. Wei S-Z, Zhan P, Shi M, et al (2011). Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol, 28, 315-21. https://doi.org/10.1007/s12032-010-9443-1
  15. William WN Jr, Lin HY, et al (2009). Revisiting stage IIIB and IV non-small cell lung cancer: Analysis of the surveillance, epidemiology, and end results data. Chest, 136, 701-9. https://doi.org/10.1378/chest.08-2968
  16. Wolfe KJ, Wickliffe JK, Hill CE, et al (2007). Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genom, 17, 897-905. https://doi.org/10.1097/FPC.0b013e3280115e63
  17. Wu Q, Christensen LA, Legerski RJ, et al (2005). Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. Embo Reports, 6, 551-6. https://doi.org/10.1038/sj.embor.7400418
  18. Yin M, Yan J, Voutsina A, et al (2011). No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer, 72, 370-7. https://doi.org/10.1016/j.lungcan.2010.10.011
  19. Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. https://doi.org/10.7314/APJCP.2012.13.6.2583

Cited by

  1. mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2987
  2. Prediction of Chemotherapeutic Response in Unresectable Non-small-cell Lung Cancer (NSCLC) Patients by 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) Assay vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.3057
  3. Polymorphisms in XPD Gene Could Predict Clinical Outcome of Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer Patients: A Meta-Analysis of 24 Studies vol.8, pp.11, 2013, https://doi.org/10.1371/journal.pone.0079864
  4. ERCC1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4117
  5. Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7453
  6. Interaction of XRCC1 and XPD Gene Polymorphisms with Lifestyle and Environmental Factors Regarding Susceptibility to Lung Cancer in a High Incidence Population in North East India vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.1993
  7. Expression of ERCC1, MSH2 and PARP1 in Non-small Cell Lung Cancer and Prognostic Value in Patients Treated with Platinum-based Chemotherapy vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2591
  8. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer vol.31, pp.8, 2014, https://doi.org/10.1007/s12032-014-0086-5
  9. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis vol.35, pp.4, 2014, https://doi.org/10.1007/s13277-013-1493-5
  10. Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer vol.35, pp.6, 2014, https://doi.org/10.1007/s13277-014-1732-4
  11. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? vol.5, pp.1664-8021, 2014, https://doi.org/10.3389/fgene.2014.00391
  12. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine vol.17, pp.12, 2016, https://doi.org/10.2217/pgs-2016-0074
  13. Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy vol.13, pp.29, 2017, https://doi.org/10.2217/fon-2017-0211
  14. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems vol.34, pp.4, 2017, https://doi.org/10.1007/s12032-017-0905-6
  15. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis vol.7, pp.1, 2017, https://doi.org/10.1038/s41598-017-05642-0
  16. XPC Polymorphism and Risk for Lung Cancer in North Indian Patients Treated with Platinum Based Chemotherapy and Its Association with Clinical Outcomes pp.1532-2807, 2017, https://doi.org/10.1007/s12253-017-0252-0